| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| Astragalosides | Diabetes | 3 | PM | 38439832 | 📋 | A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications |
| Astragalosides | Diabetes | 4 | PM | 35046684 | 📋 | Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways |
| Astragalosides | Diabetes | 1 | PM | 33706619 | 📋 | Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats |
| Astragalosides | Diabetes | 2 | PM | 28579878 | 📋 | The Effect of Different Proportions of Astragaloside and Curcumin on DM Model of Mice |
| Astragalosides | Diabetes Type 2 | 2 | PM | 35047042 | 📋 | Protective Effects of Astragaloside IV on Uric Acid-Induced Pancreatic β-Cell Injury through PI3K/AKT Pathway Activation |
| Astragalosides | Diabetes Type 2 | 1 | PM | 34438030 | 📋 | Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway |
| Astragalosides | Diabetic Cardiomyopathy | 5 | PM | 36882189 | 📋 | Astragaloside IV attenuates myocardial dysfunction in diabetic cardiomyopathy rats through downregulation of CD36-mediated ferroptosis |
| Astragalosides | Diabetic Cardiomyopathy | 4 | PM | 34395418 | 📋 | Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function |
| Astragalosides | Diabetic Cardiomyopathy | 3 | PM | 32244194 | 📋 | Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM |
| Astragalosides | Diabetic Cardiomyopathy | 2 | PM | 31713440 | 📋 | Astragaloside-IV Protects H9C2(2-1) Cardiomyocytes From High Glucose-Induced Injury via miR-34a-mediated Autophagy Pathway |
| Astragalosides | Diabetic Cardiomyopathy | 1 | PM | 31702040 | 📋 | Astragaloside IV Alleviates Myocardial Damage Induced by Type 2 Diabetes via Improving Energy Metabolism |
| Astragalosides | Diabetic Complications | 5 | PM | 35341134 | 📋 | Astragaloside IV Improves the Barrier Damage in Diabetic Glomerular Endothelial Cells Stimulated by High Glucose and High Insulin |
| Astragalosides | Diabetic Complications | 4 | PM | 33846768 | 📋 | Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy |
| Astragalosides | Diabetic Complications | 2 | PM | 30906223 | 📋 | Astragaloside IV Suppresses High Glucose-Induced NLRP3 Inflammasome Activation by Inhibiting TLR4/NF- κ B and CaSR |
| Astragalosides | Diabetic Complications | 1 | PM | 29218088 | 📋 | Effect of astragaloside IV on diabetic gastric mucosa in vivo and in vitro |
| Astragalosides | Diabetic Complications | 3 | PM | 19681610 | 📋 | Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products |
| Astragalosides | Diabetic Encephalopathy | 2 | PM | 37097336 | 📋 | Astragaloside IV-mediated inhibition of oxidative stress by upregulation of ghrelin in type 2 diabetes-induced cognitive impairment |
| Astragalosides | Diabetic Encephalopathy | 1 | PM | 36247985 | 📋 | Astragaloside IV supplementation attenuates cognitive impairment by inhibiting neuroinflammation and oxidative stress in type 2 diabetic mice |
| Astragalosides | Diabetic Ketoacidosis | 1 | PM | 32624270 | 📋 | Astragaloside IV as Potential Antioxidant Against Diabetic Ketoacidosis in Juvenile Mice Through Activating JNK/Nrf2 Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 40 | PM | 38572426 | 📋 | Astragaloside IV attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation |
| Astragalosides | Diabetic Nephropathy | 39 | PM | 38389170 | 📋 | Astragaloside IV Mitigated Diabetic Nephropathy by Restructuring Intestinal Microflora and Ferroptosis |
| Astragalosides | Diabetic Nephropathy | 38 | PM | 37751175 | 📋 | Astragaloside IV Inhibited Podocyte Pyroptosis in Diabetic Kidney Disease by Regulating SIRT6/HIF-1α Axis |
| Astragalosides | Diabetic Nephropathy | 28 | PM | 37261217 | 📋 | Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF- κ B/NLRP3 Axis |
| Astragalosides | Diabetic Nephropathy | 27 | PM | 37189016 | 📋 | Astragaloside IV attenuates high glucose-induced NF-κB-mediated inflammation through activation of PI3K/AKT-ERK-dependent Nrf2/ARE signaling pathway in glomerular mesangial cells |
| Astragalosides | Diabetic Nephropathy | 26 | PM | 37150034 | 📋 | The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease |
| Astragalosides | Diabetic Nephropathy | 25 | PM | 37030337 | 📋 | Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease |
| Astragalosides | Diabetic Nephropathy | 24 | PM | 35669284 | 📋 | Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease |
| Astragalosides | Diabetic Nephropathy | 23 | PM | 35510516 | 📋 | Mitogen-activating protein kinase kinase kinase kinase-3, inhibited by Astragaloside IV through H3 lysine 4 monomethylation, promotes the progression of diabetic nephropathy by inducing apoptosis |
| Astragalosides | Diabetic Nephropathy | 22 | PM | 34278447 | 📋 | Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome‑mediated inflammation |
| Astragalosides | Diabetic Nephropathy | 21 | PM | 33796024 | 📋 | Astragaloside II Ameliorated Podocyte Injury and Mitochondrial Dysfunction in Streptozotocin-Induced Diabetic Rats |
| Astragalosides | Diabetic Nephropathy | 20 | PM | 33606151 | 📋 | Astragaloside IV inhibits palmitic acid-induced apoptosis through regulation of calcium homeostasis in mice podocytes |
| Astragalosides | Diabetic Nephropathy | 19 | PM | 33476631 | 📋 | Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy |
| Astragalosides | Diabetic Nephropathy | 18 | PM | 32942018 | 📋 | Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis |
| Astragalosides | Diabetic Nephropathy | 17 | PM | 32855769 | 📋 | Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation |
| Astragalosides | Diabetic Nephropathy | 16 | PM | 32774716 | 📋 | Astragaloside IV alleviates puromycin aminonucleoside-induced podocyte cytoskeleton injury through the Wnt/PCP pathway |
| Astragalosides | Diabetic Nephropathy | 15 | PM | 32695006 | 📋 | Protective Effect and Possible Mechanisms of Astragaloside IV in Animal Models of Diabetic Nephropathy: A Preclinical Systematic Review and Meta-Analysis |
| Astragalosides | Diabetic Nephropathy | 1 | PM | 32339782 | 📋 | Astragaloside IV Acts Through Multi-Scale Mechanisms to Effectively Reduce Diabetic Nephropathy |
| Astragalosides | Diabetic Nephropathy | 8 | PM | 31805910 | 📋 | Astragaloside IV Protects Against Diabetic Nephropathy via Activating eNOS in Streptozotocin Diabetes-Induced Rats |
| Astragalosides | Diabetic Nephropathy | 7 | PM | 31572545 | 📋 | Astragaloside IV Inhibits Excessive Mesangial Cell Proliferation and Renal Fibrosis Caused by Diabetic Nephropathy via Modulation of the TGF-β1/Smad/miR-192 Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 12 | PM | 31086575 | 📋 | Astragaloside IV Ameliorates High Glucose-Induced HK-2 Cell Apoptosis and Oxidative Stress by Regulating the Nrf2/ARE Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 13 | PM | 30483732 | 📋 | Astragaloside IV Ameliorates High glucose‑induced Renal Tubular epithelial‑mesenchymal Transition by Blocking mTORC1/p70S6K Signaling in HK‑2 Cells |
| Astragalosides | Diabetic Nephropathy | 10 | PM | 30425453 | 📋 | Combination of Ginsenoside Rg1 and Astragaloside IV Reduces Oxidative Stress and Inhibits TGF-β1/Smads Signaling Cascade on Renal Fibrosis in Rats With Diabetic Nephropathy |
| Astragalosides | Diabetic Nephropathy | 4 | PM | 30233141 | 📋 | Astragaloside IV/lncRNA-TUG1/TRAF5 Signaling Pathway Participates in Podocyte Apoptosis of Diabetic Nephropathy Rats |
| Astragalosides | Diabetic Nephropathy | 6 | PM | 30122901 | 📋 | Astragaloside IV Improves Renal Function and Fibrosis via Inhibition of miR-21-induced Podocyte Dedifferentiation and Mesangial Cell Activation in Diabetic Mice |
| Astragalosides | Diabetic Nephropathy | 3 | PM | 29896981 | 📋 | Astragaloside IV Ameliorates Early Diabetic Nephropathy by Inhibition of MEK1/2-ERK1/2-RSK2 Signaling in Streptozotocin-Induced Diabetic Mice |
| Astragalosides | Diabetic Nephropathy | 9 | PM | 29792879 | 📋 | Astragaloside Suppresses Apoptosis of the Podocytes in Rats With Diabetic Nephropathy via miR-378/TRAF5 Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 2 | PM | 28767702 | 📋 | Astragaloside IV Ameliorates Diabetic Nephropathy by Modulating the Mitochondrial Quality Control Network |
| Astragalosides | Diabetic Nephropathy | 37 | PM | 28761152 | 📋 | Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy |
| Astragalosides | Diabetic Nephropathy | 5 | PM | 28066247 | 📋 | Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress Through Upregulating Sarco/Endoplasmic Reticulum Ca 2+-ATPase 2 Expression in Diabetic Nephropathy |
| Astragalosides | Diabetic Nephropathy | 11 | PM | 27585918 | 📋 | Astragaloside IV Ameliorates Renal Injury in db/db Mice |
| Astragalosides | Diabetic Nephropathy | 34 | PM | 27313676 | 📋 | Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells |
| Astragalosides | Diabetic Nephropathy | 14 | PM | 27109610 | 📋 | Astragaloside IV Prevents High Glucose-Induced Podocyte Apoptosis via Downregulation of TRPC6 |
| Astragalosides | Diabetic Nephropathy | 36 | PM | 26261569 | 📋 | Astragaloside effect on TGF-β1, SMAD2/3, and α-SMA expression in the kidney tissues of diabetic KKAy mice |
| Astragalosides | Diabetic Nephropathy | 35 | PM | 26125738 | 📋 | Effects of Astragaloside IV on diabetic nephropathy in rats |
| Astragalosides | Diabetic Nephropathy | 33 | PM | 25886386 | 📋 | Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress |
| Astragalosides | Diabetic Nephropathy | 29 | PM | 24718766 | 📋 | Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions |
| Astragalosides | Diabetic Nephropathy | 32 | PM | 23719694 | 📋 | Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells |
| Astragalosides | Diabetic Nephropathy | 30 | PM | 23434274 | 📋 | Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression |
| Astragalosides | Diabetic Nephropathy | 31 | PM | 22745830 | 📋 | Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo |
| Astragalosides | Diabetic Neuropathy | 4 | PM | 38254301 | 📋 | Co-treatment of Astragaloside IV with Vitamin D in Diabetic Peripheral Neuropathic Rats: Protective Effects and Potential Mechanisms |
| Astragalosides | Diabetic Neuropathy | 3 | PM | 35069769 | 📋 | Regulatory Effects of Astragaloside IV on Hyperglycemia-Induced Mitophagy in Schwann Cells |
| Astragalosides | Diabetic Neuropathy | 2 | PM | 34601220 | 📋 | Astragaloside IV alleviates Schwann cell injury in diabetic peripheral neuropathy by regulating microRNA-155-mediated autophagy |
| Astragalosides | Diabetic Neuropathy | 1 | PM | 33883914 | 📋 | Astragaloside IV Inhibits Mitochondrial-Dependent Apoptosis of the Dorsal Root Ganglion in Diabetic Peripheral Neuropathy Rats Through Modulation of the SIRT1/p53 Signaling Pathway |
| Astragalosides | Diabetic Retinopathy | 6 | PM | 38286267 | 📋 | Discovery of Astragaloside IV against high glucose-induced apoptosis in retinal ganglion cells: bioinformatics and in vitro studies |
| Astragalosides | Diabetic Retinopathy | 3 | PM | 35814228 | 📋 | A Mechanistic Exploratory Study on the Therapeutic Efficacy of Astragaloside IV Against Diabetic Retinopathy Revealed by Network Pharmacology |
| Astragalosides | Diabetic Retinopathy | 2 | PM | 35302431 | 📋 | Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2 |
| Astragalosides | Diabetic Retinopathy | 1 | PM | 32626913 | 📋 | Astragaloside IV protects retinal pigment epithelial cells from apoptosis by upregulating miR‑128 expression in diabetic rats |
| Astragalosides | Diabetic Retinopathy | 5 | PM | 29263652 | 📋 | Astragaloside IV protects rat retinal capillary endothelial cells against high glucose-induced oxidative injury |
| Astragalosides | Diabetic Retinopathy | 4 | PM | 23158272 | 📋 | [Protective effects of astragaloside IV on high-glucose-induced damage of retinal ganglion cells] |
| Astragalosides | Diabetic Ulcers and Sores | 3 | PM | 38533358 | 📋 | Effect of total astragalosides on diabetic non-healing wound by regulating immune microenvironment |
| Astragalosides | Diabetic Ulcers and Sores | 2 | PM | 36028386 | 📋 | Astragaloside IV attenuates high glucose-induced human keratinocytes injury via TGF-β/Smad signaling pathway |
| Astragalosides | Diabetic Ulcers and Sores | 1 | PM | 27016716 | 📋 | Astragaloside IV Enhances Diabetic Wound Healing Involving Upregulation of Alternatively Activated Macrophages |
| Astragalosides | Diabetic Vasculopathy | 3 | PM | 34584542 | 📋 | Astragaloside IV prevents endothelial dysfunction by improving oxidative stress in streptozotocin-induced diabetic mouse aortas |
| Astragalosides | Diabetic Vasculopathy | 1 | PM | 30628687 | 📋 | Astragaloside IV Prevents High glucose‑induced Cell Apoptosis and Inflammatory Reactions Through Inhibition of the JNK Pathway in Human Umbilical Vein Endothelial Cells |
| Astragalosides | Diabetic Vasculopathy | 2 | PM | 25224628 | 📋 | Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats |
| Astragalosides | Gestational Diabetes | 3 | PM | 33006955 | 📋 | Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice |
| Astragalosides | Gestational Diabetes | 2 | PM | 32160476 | 📋 | Astragaloside IV Relieves Gestational Diabetes Mellitus in Genetic Mice Through Reducing Hepatic Gluconeogenesis |
| Astragalosides | Gestational Diabetes | 1 | PM | 31558153 | 📋 | Astragaloside IV Attenuates Gestational Diabetes Mellitus via Targeting NLRP3 Inflammasome in Genetic Mice |
| Astragalosides | Hyperglycemia | 4 | PM | 36631922 | 📋 | Astragaloside IV (ASIV) Mediates Endothelial Progenitor Cell (EPC) Exosomal LINC01963 to Inhibit Pyroptosis and Oxidative Stress in High Glucose-impaired Endothelial Cells |
| Astragalosides | Hyperglycemia | 3 | PM | 34438030 | 📋 | Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway |
| Astragalosides | Hyperglycemia | 2 | PM | 33706619 | 📋 | Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats |
| Astragalosides | Hyperglycemia | 1 | PM | 31323271 | 📋 | Astragaloside IV Protects Against Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Oxidative Stress and Calpain-1 Activation |
| Astragalosides | Hyperglycemia | 5 | PM | 19610026 | 📋 | Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin |
